Sanofi-Aventis Sa (SNY) 39.18 $SNY
Sanofi-Aventis Rises 1.80% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Sep 02, 3:19PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.02 to a high of $39.30. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $38.99 on volume of 729,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 39.18 (+0.77)
Watch for Sanofi-Aventis to Potentially Pullback After Gaining 1.80% Yesterday
Comtex SmarTrend(R) - Fri Sep 02, 3:17PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.02 to a high of $39.30. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $38.99 on volume of 729,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 39.18 (+0.77)
The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 38.31 (-0.66), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Mylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:41AM CDT
Mylan's (MYL) shares took a beating after U.S. senators raised questions about the company's massive price hike of epinephrine auto-injector, EpiPen.
ANIP: 59.86 (-1.56), MYL: 39.97 (-1.95), SNY: 39.18 (+0.77)
Regeneron Stock Up on BARDA Deal for MERS Antibodies
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:48AM CDT
Regeneron Pharmaceuticals (REGN) has signed up with BARDA for the development of treatments targeting MERS viru
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 3:50AM CDT
Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
Pfizer (PFE) Bought Medivation (MDVN), but is it a Good Deal?
Maher Syed - Zacks Investment Research - Mon Aug 22, 4:06PM CDT
Pfizer is paying $14 billion for Medivation Inc, but is it worth it?
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
Pfizer-Medivation Close to Signing $14B Acquisition Deal? (revised)
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 3:13PM CDT
Sanofi had initially approached Medivation with an offer of $52.50 in cash which was rejected by the company.
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
ETFs in Focus on Pfizer's Medivation Acquisition
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 11:01AM CDT
The pharma giant, Pfizer (PFE) announced to acquire Medivation (MDVN) for $14 billion.
IHE: 147.95 (-0.83), MDVN: 80.85 (-0.08), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), PFE: 34.77 (+0.09), FHLC: 34.54 (+0.03), SNY: 39.18 (+0.77), VHT: 133.16 (+0.19), XLV: 72.65 (+0.08), CELG: 105.49 (-0.88)
Sanofi Diabetes Combination Drug FDA Action Date Extended
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 8:29AM CDT
Sanofi (SNY) submitted updated information on the pen delivery device as part of its NDA for the fixed-ratio combination.
CBM: 43.27 (+0.10), GERN: 2.75 (+0.02), SNY: 39.18 (+0.77)
Pfizer to Buy Medivation for $14B, Boost Cancer Franchise
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 7:31AM CDT
Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
Pfizer-Medivation Close to Signing $14B Acquisition Deal?
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 2:54AM CDT
The Medivation (MDVN) acquisition, if it goes through, will boost Pfizer's (PFE) oncology business and pipeline.
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
Immune Design (IMDZ) Posts Wider-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 2:45PM CDT
Immune Design (IMDZ) reported a wider-than-expected loss in the second quarter.
IMDZ: 7.07 (-0.04), MRK: 62.98 (+0.08), SNY: 39.18 (+0.77), PCRX: 39.04 (-1.33)
SmarTrend Watching for Potential Rebound in Shares of Sanofi-Aventis After 1.65% Loss
Comtex SmarTrend(R) - Wed Aug 10, 2:29PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.64 to a high of $40.04. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $39.92 on volume of 868,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SNY: 39.18 (+0.77)
Sanofi-Aventis Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Wed Aug 10, 2:28PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.64 to a high of $40.04. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $39.92 on volume of 868,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SNY: 39.18 (+0.77)
BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:34AM CDT
BioMarin Pharmaceutical (BMRN) reported a narrower-than-expected second-quarter 2016 loss of 11 cents per shares; revenues beat estimates while the view was upped.
BMRN: 95.73 (+0.54), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05), SNY: 39.18 (+0.77)
Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 10:33AM CDT
Regeneron Pharmaceuticals (REGN) reported better-than-expected second-quarter 2016 earnings of $2.10 per share.
ANIP: 59.86 (-1.56), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Sanofi-Aventis Rises 1.80% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Sep 02, 3:19PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.02 to a high of $39.30. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $38.99 on volume of 729,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 39.18 (+0.77)
Watch for Sanofi-Aventis to Potentially Pullback After Gaining 1.80% Yesterday
Comtex SmarTrend(R) - Fri Sep 02, 3:17PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.02 to a high of $39.30. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $38.99 on volume of 729,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SNY: 39.18 (+0.77)
The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 38.31 (-0.66), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
SAN: 4.56 (+0.04), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Mylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:41AM CDT
Mylan's (MYL) shares took a beating after U.S. senators raised questions about the company's massive price hike of epinephrine auto-injector, EpiPen.
ANIP: 59.86 (-1.56), MYL: 39.97 (-1.95), SNY: 39.18 (+0.77)
Regeneron Stock Up on BARDA Deal for MERS Antibodies
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:48AM CDT
Regeneron Pharmaceuticals (REGN) has signed up with BARDA for the development of treatments targeting MERS viru
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 3:50AM CDT
Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
Pfizer (PFE) Bought Medivation (MDVN), but is it a Good Deal?
Maher Syed - Zacks Investment Research - Mon Aug 22, 4:06PM CDT
Pfizer is paying $14 billion for Medivation Inc, but is it worth it?
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
Pfizer-Medivation Close to Signing $14B Acquisition Deal? (revised)
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 3:13PM CDT
Sanofi had initially approached Medivation with an offer of $52.50 in cash which was rejected by the company.
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
ETFs in Focus on Pfizer's Medivation Acquisition
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 11:01AM CDT
The pharma giant, Pfizer (PFE) announced to acquire Medivation (MDVN) for $14 billion.
IHE: 147.95 (-0.83), MDVN: 80.85 (-0.08), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), PFE: 34.77 (+0.09), FHLC: 34.54 (+0.03), SNY: 39.18 (+0.77), VHT: 133.16 (+0.19), XLV: 72.65 (+0.08), CELG: 105.49 (-0.88)
Sanofi Diabetes Combination Drug FDA Action Date Extended
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 8:29AM CDT
Sanofi (SNY) submitted updated information on the pen delivery device as part of its NDA for the fixed-ratio combination.
CBM: 43.27 (+0.10), GERN: 2.75 (+0.02), SNY: 39.18 (+0.77)
Pfizer to Buy Medivation for $14B, Boost Cancer Franchise
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 7:31AM CDT
Pfizer (PFE) is buying cancer-focused Medivation for $14 billion with the deal slated to close in the third or fourth quarter.
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
Pfizer-Medivation Close to Signing $14B Acquisition Deal?
Arpita Dutt - Zacks Investment Research - Mon Aug 22, 2:54AM CDT
The Medivation (MDVN) acquisition, if it goes through, will boost Pfizer's (PFE) oncology business and pipeline.
MDVN: 80.85 (-0.08), PFE: 34.77 (+0.09), SNY: 39.18 (+0.77)
Immune Design (IMDZ) Posts Wider-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 2:45PM CDT
Immune Design (IMDZ) reported a wider-than-expected loss in the second quarter.
IMDZ: 7.07 (-0.04), MRK: 62.98 (+0.08), SNY: 39.18 (+0.77), PCRX: 39.04 (-1.33)
SmarTrend Watching for Potential Rebound in Shares of Sanofi-Aventis After 1.65% Loss
Comtex SmarTrend(R) - Wed Aug 10, 2:29PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.64 to a high of $40.04. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $39.92 on volume of 868,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SNY: 39.18 (+0.77)
Sanofi-Aventis Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Wed Aug 10, 2:28PM CDT
Sanofi-Aventis (NYSE:SNY) traded in a range yesterday that spanned from a low of $39.64 to a high of $40.04. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $39.92 on volume of 868,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SNY: 39.18 (+0.77)
BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:34AM CDT
BioMarin Pharmaceutical (BMRN) reported a narrower-than-expected second-quarter 2016 loss of 11 cents per shares; revenues beat estimates while the view was upped.
BMRN: 95.73 (+0.54), GERN: 2.75 (+0.02), ANIK: 47.89 (-0.05), SNY: 39.18 (+0.77)
Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 10:33AM CDT
Regeneron Pharmaceuticals (REGN) reported better-than-expected second-quarter 2016 earnings of $2.10 per share.
ANIP: 59.86 (-1.56), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
